Merck Remains Committed to RNAi Despite Shuttering Its California Facility
August 04, 2011
Merck Remains Committed to RNAi Despite Shuttering Its California Facility
Merck confirmed that it is closing the San Francisco RNAi R&D facility it picked up through its acquisition of Sirna Therapeutics, but a spokesperson said that the company has not reduced its investment in the technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.